Evidence map›Paper›PMID 39182213›Full record

ArticleClinical rheumatology2024

Long-term outcomes of infliximab treatment in neuro-Behcet syndrome: A single-center retrospective study.

Koc Emine Rabia, Güllü Gizem, Saridas Furkan, Gluscevic Sanja, Coskun Belkıs Nihan, Pehlivan Yavuz, Calikusu Fatma Zehra, Turan Omer Faruk

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Neuro-behcet's syndrome: epidemiology, mechanisms, and emerging strategies in diagnosis and treatment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Koc Emine RabiaFaculty of Medicine, Department of Neurology, Uludag University, Bursa, Turkey. erabiakoc@uludag.edu.tr.ORCID http://orcid.org/0000-0002-0264-7284
Güllü GizemBursa Şevket Yılmaz Training and Research Hospital, Neurology, Bursa, Turkey.ORCID http://orcid.org/0000-0001-9477-5031
Saridas FurkanFaculty of Medicine, Department of Neurology, Uludag University, Bursa, Turkey.ORCID http://orcid.org/0000-0001-5945-2317
Gluscevic SanjaClinical Centre of Montenegro, Clinic for Neurology, Podgorica, Montenegro.ORCID http://orcid.org/0000-0002-9230-9093
Coskun Belkıs NihanFaculty of Medicine, Department of Rheumatology, Uludag University, Bursa, Turkey.ORCID http://orcid.org/0000-0003-0298-4157
Pehlivan YavuzFaculty of Medicine, Department of Rheumatology, Uludag University, Bursa, Turkey.ORCID http://orcid.org/0000-0002-1201-8836
Calikusu Fatma ZehraFaculty of Medicine, Department of Neurology, Uludag University, Bursa, Turkey.ORCID http://orcid.org/0000-0002-6644-6553
Turan Omer FarukFaculty of Medicine, Department of Neurology, Uludag University, Bursa, Turkey.ORCID http://orcid.org/0000-0002-6752-1519

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBehcet's syndrome is a rare inflammatory disorder characterized by oral and genital ulcers, skin lesions, and uveitis. It exhibits a higher prevalence along the historic Silk Road. Neuro-Behcet syndrome (NBS) affects the central nervous system and poses significant morbidity and mortality risks. Infliximab, a TNF-alpha antagonist, has shown potential in NBS management, although the current evidence is mainly derived from case series due to the lack of randomized controlled trials.

objectiveThis retrospective study aimed to evaluate the disease outcomes during the first and second years following infliximab treatment in NBS patients experiencing attacks despite prior conventional immunosuppressive therapy. The study also sought to investigate the safety profile and adverse effects associated with infliximab.

methodsFifty-three NBS patients were examined, with 22 receiving infliximab as either monotherapy or in combination with other therapies. Retrospective analysis was conducted on demographic data, clinical characteristics, and treatment responses. Treatment efficacy was measured using the Expanded Disability Status Scale (EDSS) modified for NBS. The study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist guidelines.

resultsAmong the study cohort, 60.4% had parenchymal NBS, and 39.6% had nonparenchymal NBS. Treatment with infliximab resulted in remission or disease stabilization in 95% of patients after one year and 68.7% after 2 years. Relapse rates were 4.5% at 1 year and 18.7% at 2 years, with disease progression observed in two cases. Adverse effects were primarily mild to moderate, with no reports of serious adverse events.

conclusionInfliximab exhibited efficacy in achieving remission or stabilization in NBS patients, maintaining a favorable safety profile. The timing of infliximab treatment may prevent the accumulation of disability and hinder disease progression. Nonetheless, future prospective studies are necessary to confirm these findings and refine treatment strategies for this complex condition.

Indexed as

Behcet SyndromeInfliximabAdultFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultInfliximabAnti-TNF alpha agentsBehcet syndromeInfliximabNeuro-Behcet syndrome

Identifiers

PMID39182213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.